The Bulletin
Men's Weekly


.

Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment

  • Written by The Bulletin
  • Berlin Cures, a clinical-stage biotechnology firm, advances innovative treatment aimed at combating Long COVID, currently impacting over 100 million people globally.
  • Over 50% of patients in randomized placebo-controlled Phase-II-trial now recruited; no issues regarding safety observed.

Read more: Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient...